Skip to main content
European Commission logo print header

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Project description

Digital sensors to monitor mobility, disease progression

Clinicians, scientists, prominent academic centres, businesses, and the world’s largest pharmaceutical and medical industries are working together to develop a revolutionary sensor system to monitor gait in daily life. Mobility is considered the ‘sixth vital sign’ of health, with poor gait such as walking slowly being associated with greater risk of disease, cognitive decline, risk of falls, and even earlier death. The Mobilise-D project will develop digital technology, including body-worn sensors, to monitor mobility. They aim to deliver a solution for real-world digital mobility assessment and validate digital mobility outcomes to predict clinical endpoints in multiple sclerosis, hip fracture recovery, chronic obstructive pulmonary disease, and Parkinson’s disease. The results will facilitate drug development and establish a roadmap for the clinical implementation of new digital tools to identify, stratify, and monitor disability.


Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.


Net EU contribution
€ 3 590 382,85
NE1 7RU Newcastle Upon Tyne
United Kingdom

See on map

North East (England) Northumberland and Tyne and Wear Tyneside
Activity type
Higher or Secondary Education Establishments
Total cost
€ 4 297 692,00

Participants (37)